Having trouble accessing articles? Reset your cache.

Telaprevir: Phase III data

In the double-blind, international Phase III REALIZE trial in 662 patients with HCV genotype 1 infection who failed previous therapy, simultaneous-start and delayed-start telaprevir regimens plus standard of care (SOC; Pegasys peginterferon alfa-2a and Copegus ribavirin) each met the primary endpoint of

Read the full 424 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers